Who are Cyramza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cometriq, Cometriq, Nexavar, Vermox, Rivoceranib, Ramucirumab (IMC-1211B) DP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramucirumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Cyramza — Competitive Intelligence Brief

Cyramza (RAMUCIRUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]. Area: Oncology.

marketed Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] Vascular endothelial growth factor receptor 2 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Cyramza (RAMUCIRUMAB) — Eli Lilly. Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyramza TARGET	RAMUCIRUMAB	Eli Lilly	marketed	Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]	Vascular endothelial growth factor receptor 2	2014-01-01
Cometriq	Cabometyx	Exelixis	marketed	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Cometriq	CABOZANTINIB	Exelixis Inc	marketed	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Nexavar	SORAFENIB	Bayer	marketed	Kinase Inhibitor [EPC]	Vascular endothelial growth factor receptor 2	2005-01-01
Vermox	MEBENDAZOLE		marketed	Anthelmintic [EPC]	Vascular endothelial growth factor receptor 2	1974-01-01
Rivoceranib	Apatinib	Zhongda Hospital	marketed		Vascular endothelial growth factor receptor 2
Ramucirumab (IMC-1211B) DP	Ramucirumab (IMC-1211B) DP	Eli Lilly and Company	phase 3	VEGFR2 inhibitor (monoclonal antibody)	VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-14 — Cometriq · 7579473 · US
2030-01-15 — Cometriq · 11091439 · US
2030-01-15 — Cometriq · 11098015 · US
2030-01-15 — Cometriq · 11091440 · US
2030-10-08 — Cometriq · 8877776 · US
2031-07-18 — Cometriq · 10034873 · US
2031-07-18 — Cometriq · 10039757 · US
2032-02-10 — Cometriq · 11298349 · US
2032-02-10 — Cometriq · 9717720 · US
2033-07-09 — Cometriq · 9724342 · US

Sponsor landscape (Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] class)

Eli Lilly · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyramza — Competitive Intelligence Brief. https://druglandscape.com/ci/ramucirumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab